FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2987284328> ?p ?o ?g. }

• W2987284328 endingPage "5112" @default.
• W2987284328 startingPage "5112" @default.
• W2987284328 abstract "Objectives Acute Myeloid leukemia (AML) is a heterogeneous disease with high morbidity and mortality. These patients can be stratified into favorable, intermediate and adverse-risk groups based on their cytogenetic and molecular profile. We analyzed the outcomes of the intermediate risk patients in our center to evaluate the results and to report the differences between the intensity of the treatments, chemotherapy alone versus allogeneic stem cell transplantation (SCT). Methods A total of 53 patients diagnosed in Hospital Universitari Son Espases between 2012 and 2019 with AML, classified as intermediate risk disease (based on ELN 2017 criteria), and candidates to intensive treatment were analyzed. Results The median age at diagnosis was 61 years (range 17-74), 28 males and 25 females. Regarding the diagnosis, almost 50% were AML with mutated NPM1, AML with myelodysplasia-related changes and AML therapy-related. Thirty percent of the patients had FLT3-ITD mutation (78.6% of them with high ratio). Twenty eight percent had NPM1 mutation. The 75.5% received cytarabine and anthracycline induction chemotherapy and the remaining 24.5% received a combination of cytarabine, anthracycline plus etoposide. Twenty percent of the patients (11) died during the induction therapy, the main of them due to infections. Of the 42 patients alive, 36 (85.7%) achieved a complete remission, 4 a partial response (9.5 %) and 2 patients (4.8%) were refractory. All of the patients went under consolidation: 39 (73.5%) with chemotherapy alone and 14 (33 %) with SCT (4 of them immediately after salvage therapy without hematopoietic recovery). Three patients received a HLA identical sibling SCT (21.4%), 3 a matched unrelated donor (21.4%), 5 (35.7%) an haploidentical SCT, 1 patient (7.1%) a cord blood stem cell transplantation and 2 patients an autologous SCT (14.3%). The median follow-up of the whole group of patients was 22 months (2.6-86). The median overall survival (OS) was 18 months (CI 95%: 10-25) and the median progression free survival (PFS) was 9 months (CI 95%: 4- 14). Patients who went under transplantation achieved a PFS of 18.5 months compared with 7.8 months in no transplantation patients (p=0.159). Patients with non-mutated FLT3-ITD have a median PFS of 14 months compared with 7 months in patients with mutated FLT3-ITD (p=0.333). Excluding the patients who died during induction therapy, 11 patients with mutated FLT3-ITD went into consolidation therapy. Three received SCT and 8 chemotherapy alone. The median OS of the SCT group was 18.5 versus 13.6 months in the chemotherapy group (CI 95% 4.3-22.9; p=0.4). The median PFS of the SCT group was 6.17 months (CI 95% 2.06-10.3), similar to the chemotherapy group where was 7.6 months (CI 95% 5.03-10.66; p=0.7). Twenty-eight patients with non-mutated FLT3-ITD received consolidation therapy, 6 of them went into SCT. OS in the transplant group was 46.4 months (CI 95%: 44.6-48.2; p= 0.4) compared with 35.3 months (CI 95%: 11.7- 58.3; p=0.4) in the non-transplantation group. PFS of transplant group was 18.1 month (CI 95%: 9.5-26.22) superior to PFS in chemotherapy group that was 9.4 months (CI 4.65-14; p=0.7). Patients with mutated FLT3-ITD who did not received an FLT3 tyrosine kinase inhibitor (TKI) had a PFS of 6 months (0-13.8) compared with those that received an FLT3 TKI who did not reach the median survival rate. Conclusions Our outcomes are similar to the ones described in the literature. We confirm that patients with intermediate risk who underwent transplantation have better outcomes that the ones treated with chemotherapy alone. Moreover, we confirm that the prognosis is better in patients with non-mutated FLT3-ITD. SCT increase the OS in FLT 3-ITD mutated patients, although the PFS is similar in both groups (SCT vs chemotherapy), taking into account the small size of our sample and the short follow up period in many patients. The better outcome observed in FLT3 tyrosine kinase inhibitor treated patients indicates that this can be a promising therapy in AML patients. Disclosures No relevant conflicts of interest to declare." @default.
• W2987284328 created "2019-11-22" @default.
• W2987284328 creator A5006074198 @default.
• W2987284328 creator A5009613884 @default.
• W2987284328 creator A5020776683 @default.
• W2987284328 creator A5053284301 @default.
• W2987284328 creator A5053351265 @default.
• W2987284328 creator A5073392350 @default.
• W2987284328 creator A5089964057 @default.
• W2987284328 date "2019-11-13" @default.
• W2987284328 modified "2023-10-16" @default.
• W2987284328 title "Survival Outcomes in Patients with Intermediate Risk Acute Myeloid Leukemia: A Single-Center Retrospective Review" @default.
• W2987284328 doi "https://doi.org/10.1182/blood-2019-131987" @default.
• W2987284328 hasPublicationYear "2019" @default.
• W2987284328 type Work @default.
• W2987284328 sameAs 2987284328 @default.
• W2987284328 citedByCount "0" @default.
• W2987284328 crossrefType "journal-article" @default.
• W2987284328 hasAuthorship W2987284328A5006074198 @default.
• W2987284328 hasAuthorship W2987284328A5009613884 @default.
• W2987284328 hasAuthorship W2987284328A5020776683 @default.
• W2987284328 hasAuthorship W2987284328A5053284301 @default.
• W2987284328 hasAuthorship W2987284328A5053351265 @default.
• W2987284328 hasAuthorship W2987284328A5073392350 @default.
• W2987284328 hasAuthorship W2987284328A5089964057 @default.
• W2987284328 hasBestOaLocation W29872843281 @default.
• W2987284328 hasConcept C121608353 @default.
• W2987284328 hasConcept C126322002 @default.
• W2987284328 hasConcept C141071460 @default.
• W2987284328 hasConcept C143998085 @default.
• W2987284328 hasConcept C2776611710 @default.
• W2987284328 hasConcept C2776694085 @default.
• W2987284328 hasConcept C2776802502 @default.
• W2987284328 hasConcept C2777408962 @default.
• W2987284328 hasConcept C2778041864 @default.
• W2987284328 hasConcept C2778119113 @default.
• W2987284328 hasConcept C2778336483 @default.
• W2987284328 hasConcept C2778729363 @default.
• W2987284328 hasConcept C2780073493 @default.
• W2987284328 hasConcept C2780775027 @default.
• W2987284328 hasConcept C2911091166 @default.
• W2987284328 hasConcept C530470458 @default.
• W2987284328 hasConcept C71924100 @default.
• W2987284328 hasConceptScore W2987284328C121608353 @default.
• W2987284328 hasConceptScore W2987284328C126322002 @default.
• W2987284328 hasConceptScore W2987284328C141071460 @default.
• W2987284328 hasConceptScore W2987284328C143998085 @default.
• W2987284328 hasConceptScore W2987284328C2776611710 @default.
• W2987284328 hasConceptScore W2987284328C2776694085 @default.
• W2987284328 hasConceptScore W2987284328C2776802502 @default.
• W2987284328 hasConceptScore W2987284328C2777408962 @default.
• W2987284328 hasConceptScore W2987284328C2778041864 @default.
• W2987284328 hasConceptScore W2987284328C2778119113 @default.
• W2987284328 hasConceptScore W2987284328C2778336483 @default.
• W2987284328 hasConceptScore W2987284328C2778729363 @default.
• W2987284328 hasConceptScore W2987284328C2780073493 @default.
• W2987284328 hasConceptScore W2987284328C2780775027 @default.
• W2987284328 hasConceptScore W2987284328C2911091166 @default.
• W2987284328 hasConceptScore W2987284328C530470458 @default.
• W2987284328 hasConceptScore W2987284328C71924100 @default.
• W2987284328 hasIssue "Supplement_1" @default.
• W2987284328 hasLocation W29872843281 @default.
• W2987284328 hasOpenAccess W2987284328 @default.
• W2987284328 hasPrimaryLocation W29872843281 @default.
• W2987284328 hasRelatedWork W1970764310 @default.
• W2987284328 hasRelatedWork W2016381406 @default.
• W2987284328 hasRelatedWork W2030418865 @default.
• W2987284328 hasRelatedWork W2034612532 @default.
• W2987284328 hasRelatedWork W2527530754 @default.
• W2987284328 hasRelatedWork W2594234261 @default.
• W2987284328 hasRelatedWork W2979117532 @default.
• W2987284328 hasRelatedWork W2987284328 @default.
• W2987284328 hasRelatedWork W2998307583 @default.
• W2987284328 hasRelatedWork W3146610960 @default.
• W2987284328 hasVolume "134" @default.
• W2987284328 isParatext "false" @default.
• W2987284328 isRetracted "false" @default.
• W2987284328 magId "2987284328" @default.
• W2987284328 workType "article" @default.